Evaluating how genetics affect the effectiveness of oral contraceptive pills

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to investigate how genetic variations, specifically the CYP3A7*1C variant, influence the metabolism of hormones in oral contraceptive pills, potentially affecting their efficacy and side effects. The study will assess whether individuals with this genetic variant metabolize desogestrel and ethinyl estradiol differently and if they experience higher rates of breakthrough ovulation. By understanding these genetic factors, the trial seeks to identify novel genetic loci associated with variations in hormone pharmacokinetics and pharmacodynamics. Participants will be women aged 18-45 who are in good health and willing to adhere to the study protocols.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Female, aged 18-45 years old
4. In good general health as evidenced by medical history and no need for regular intensive medical interventions (e.g., inpatient admissions, surgical treatments). The Principal Investigator will be responsible for determining good general health for potential participants with complicated medical histories.
5. Ability to take oral medication and be willing to adhere to the oral contraceptive pill (DSG/EE) regimen
6. Body-mass index ≥18.5kg/m2
7. Willing to abstain from medications and supplements known to induce/inhibit CYP3A (e.g., rifampin, carbamazepine, ketoconazole, St. John's wort) during the study
8. Normal blood pressure measurement at study screening
9. Negative urine pregnancy test at study screening

Exclusion Criteria:

1. Currently taking any known CYP3A inducers/inhibitors (e.g., rifampin, carbamazepine, ketoconazole, St. John's wort)43
2. Any medical conditions that affect liver function (e.g., hepatitis, cirrhosis)
3. Contraindications to estrogen-containing contraception (based on category 3 or 4 recommendations in the CDC MEC guidelines42)

   1. Current breast cancer or personal history of breast cancer
   2. Severe decompensated cirrhosis
   3. Personal history of deep venous thrombosis or pulmonary embolism
   4. Recent major surgery with prolonged immobilization
   5. Diabetes with nephropathy, retinopathy, neuropathy, or other vascular disease
   6. Current gallbladder disease
   7. Migraine headaches with aura
   8. History of malabsorptive bariatric surgery
   9. History of cholestasis due to past oral contraceptive pill use
   10. Personal history of hypertension
   11. Personal history of ischemic heart disease
   12. Known thrombogenic mutations
   13. Personal history of focal nodular hyperplasia of the liver, hepatocellular adenoma, or malignant hepatoma
   14. Multiple sclerosis with prolonged immobility
   15. History of peripartum cardiomyopathy
   16. Current tobacco smoker and age ≥35 years
   17. History of complicated solid organ transplantation
   18. Personal history of stroke
   19. Personal history of superficial venous thrombosis
   20. Systemic lupus erythematosus with positive or unknown antiphospholipid antibodies
   21. Complicated valvular heart disease
   22. Current use of fosamprenavir or lamotrigine
4. Use of injectable contraceptive method within 6 months or current use of an ENG implant
5. Childbirth within 6 months

Where it's running

• University of Colorado Anschutz Medical Campus
  Aurora, Colorado, United States Recruiting
• Yale University
  New Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Aaron M Lazorwitz, MD, PhD — Yale University
• Study coordinator: Aaron M Lazorwitz, MD, PhD
• Email: aaron.lazorwitz@yale.edu
• Phone: 2037854688

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effectiveness of the Natural Cycles birth control app

  This study will test how well the Natural Cycles app prevents pregnancy over one year in sexually active women aged 18 to 35 with no known infertility.

  Recruiting Natural Cycles · New York, New York · NCT07566793

• Female Reproductive Health in the Canadian Armed Forces: Understanding Issues from Contraception to Pelvic Floor Dysfunction

  This observational study looks at reproductive health among women in the Canadian Armed Forces to see how contraception, pregnancy outcomes, infertility, pelvic floor issues, and related factors affect service members and veterans.

  Recruiting Université de Sherbrooke · Sherbrooke, Quebec · NCT07524764

• Long-acting HIV PrEP and contraception PK study in AGYW

  This study tests how long-acting cabotegravir for PrEP interacts with hormonal contraception in young women.

  Recruiting University of Alabama at Birmingham · Bontleng, Gaborone · NCT07516548

• Vasectomy: Right for Me? — a web-based decision aid

  A web-based decision aid helps men think clearly about vasectomy and other birth control options to see if it fits their goals.

  Recruiting at 2 sites University of Pittsburgh · San Francisco, California and 1 other locations · NCT07451067

• Pharmacist-guided medication management using pharmacogenomics to improve depression care

  This study tests whether pharmacists in community pharmacies can use a patient's pharmacogenomic results to guide antidepressant treatment and improve Depression outcomes compared with usual care.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07373470

• Contraceptive patch designed to stop ovulation

  This trial tests whether a norelgestromin transdermal patch can keep ovulation suppressed for 84 days even when users make intentional application mistakes, in healthy women aged 18–35.

  Recruiting Phase 2 Viatris Inc. · Berlin · NCT07365904

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.